Evidence map›Paper›PMID 40160348›Full record

ArticleOpen forum infectious diseases2025

The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy.

Nicholas T Funderburg, Allison Ross Eckard, Qian Wu, Abdus Sattar, Kate Ailstock, Morgan Cummings, Danielle Labbato, Grace A McComsey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicholas T FunderburgDivision of Medical Laboratory Sciences, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-3113-1217
Allison Ross EckardDepartments of Pediatrics and Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0000-0002-3069-7721
Qian WuSchool of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Abdus SattarSchool of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-3863-3113
Kate AilstockDivision of Medical Laboratory Sciences, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, Ohio, USA.
Morgan CummingsDivision of Medical Laboratory Sciences, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, Ohio, USA.
Danielle LabbatoDepartments of Pediatrics and Medicine, University Hospitals of Cleveland, Cleveland, Ohio, USA.
Grace A McComseySchool of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-2690-8888

Funding

Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages for Everyone's Health (CLE Health)UM1TR004528 · CASE WESTERN RESERVE UNIVERSITY · 2025 to 2025
$7.9M
NCATS NIH HHS UM1 TR004528NIDDK NIH HHS R01 DK121619
6 · The paper itself

Abstract

Background: Cardiovascular and metabolic comorbidities are common in people with HIV (PWH) and are linked to chronic inflammation and immune activation. We assessed the effects of semaglutide on plasma markers of immune activation/inflammation that are known to be increased in PWH and are associated with morbidity and mortality in this population. Methods: We conducted a single-site, randomized, double-blinded, placebo-controlled trial of virologically suppressed, nondiabetic PWH ≥18 years of age on stable antiretroviral therapy with body mass index ≥ 25 kg/m Results: A total of 108 participants were enrolled and evenly randomized to semaglutide versus placebo. Eight (15%) in each group withdrew prematurely. Thirty-two weeks of semaglutide treatment reduced baseline levels of C-reactive protein, interleukin-6, and soluble CD163 (all Conclusions: In this randomized controlled trial of semaglutide in PWH, we report significant decreases in markers of inflammation that are associated with morbidity and mortality in this population. These results add to the growing literature demonstrating the anti-inflammatory effects of semaglutide. Further studies in PWH are warranted.

Indexed as

C-reactive proteinHIV-1inflammationinterleukin-6semaglutide

Identifiers

PMID40160348
PMCPMC11950536

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.